Prostate Cancer: Androgen Deprivation Therapy Updates

Expert panelists center discussion around two patient cases to review use of newer anti-androgen deprivation therapy in the management of prostate cancer.

EP. 1: Overview on Androgen Deprivation Therapy in Prostate Cancer

April 6th 2022

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

EP. 2: ADT Therapy in Prostate Cancer: Agonists vs Antagonists

April 6th 2022

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

EP. 3: Patient Scenario 1: nmCRPC Identification and Work-up

April 13th 2022

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

EP. 4: AR Inhibitor Selection in Nonmetastatic Castration-Resistant Prostate Cancer

April 13th 2022

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

EP. 5: PSMA-Targeted Therapy for nmCRPC

April 20th 2022

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

EP. 6: Patient Scenario 2: Selecting Therapy for mHSPC

April 20th 2022

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

EP. 7: Novel Approaches to Optimizing Management of mHSPC

April 27th 2022

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

EP. 8: Genomic Testing Practices in Prostate Cancer

April 27th 2022

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

EP. 9: Triplet Combination Strategies to Manage Metastatic HSPC

May 4th 2022

Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.